GAP’s statement: Study cites limited awareness among patients and physicians, anxiety, and lack of quick diagnostics Washington, DC (August 20, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding a University of Southern California Louis D. Schaeffer Center for Health Policy & Economics white paper, “Key Barriers to […]
Washington D.C. (July 30, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding recent groundbreaking advances in Alzheimer’s blood test research: “I want to congratulate and thank Dr. Barthélemy, Dr. Horie, Dr. Sato, Dr. Bateman, Dr. Palmqvist, Dr. Janelidze, and Dr. Quiroz on their published research on two […]
Washington D.C. (July 9, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding Biogen’s submission of its BLA application for Aducanumab with the FDA: “The Alzheimer’s research community is looking forward to a thoughtful review of Aducanumab and ideally, approval by the FDA. This application represents a singular […]
June 2, 2020 The events that spurred the reaction around the country this weekend are painful reminders that injustice remains in our world. At the Global Alzheimer’s Platform Foundation® (GAP), we agree that monumental changes on local and national levels are necessary to address the issues plaguing Black and African American people in our country […]
At a pivotal time in Alzheimer’s research, the GAP Foundation and the Alzheimer’s Drug Discovery Foundation will connect funders with leading innovators Updated on March 26, 2020: The Global Alzheimer’s Platform Foundation (GAP) has announced it is postponing the GAP Innovation Summit that was to be held on May 5, 2020 with our partner, the […]
Three research volunteers given first ever national award for their essential role in combatting the greatest public health crisis for our society in this century Washington, DC (October 23, 2019) – Today, the Global Alzheimer’s Platform Foundation® (GAP) honors three Citizen Scientists® in recognition of the indispensable role clinical trial volunteers play in the fight […]
First disease-modifying drug in 16 years to be submitted for FDA approval in 2020 ***John Dwyer is available for comment today live from the National Alzheimer’s Summit in Washington, D.C.*** Washington, DC (October 22, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement on the announcement today […]
Spartan will donate $5 to the GAP Transportation Program from each sale of its rapid APOE test to GAP-Net Research Sites Ottawa, Canada (July 31, 2019) – Spartan Bioscience today announced a partnership with the Global Alzheimer’s Platform Foundation® (GAP) to help recruit possible study participants and accelerate Alzheimer’s clinical trials. Through the partnership, Spartan will donate $5 from […]
During National Citizen Scientist Week, June 17-21, GAP Honors More Than 100 Award Nominees Washington, DC (June 17, 2019) – June 17-21, 2019 is the first ever National Citizen Scientist Week, a time to honor people who volunteer for Alzheimer’s research and inspire hope for new therapies for the disease. To celebrate the contributions of the remarkable volunteers […]
NIA Makes $9 Million Multiyear Grant to Study New Therapeutic Approach, an Orally- Administered Treatment for Alzheimer’s Washington, DC (May 20, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The nearly six million Americans with Alzheimer’s and their families deserve for no scientific stone to go […]
Washington, DC (April 10, 2019) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, today issued the following statement: “The Global Alzheimer’s Platform Foundation thanks Commissioner Seema Verma and the Centers for Medicare and Medicaid Services (CMS) for its thoughtful and impactful leadership in implementing policies that will improve Medicare Advantage beneficiaries’ ability […]
GAP President Calls Memory Fitness Programs Through Medicare Advantage “a Game-Changer” Nashville (February 28, 2019)? – Global Alzheimer’s Platform Foundation (GAP) President John Dwyer today announced a roadmap for increasing participation in Alzheimer’s clinical trials by supporting and collaborating with memory fitness supplemental benefit programs offered through select Medicare Advantage plans across the United States. Dwyer […]
Researchers, recruiters, and CEOs from more than 70 Alzheimer’s clinical trial sites to share strategies on finding a cure for the deadly disease From February 27 – March 1, the Global Alzheimer’s Platform Foundation (GAP), an organization dedicated to speeding and improving Alzheimer’s clinical trials in pursuit of a cure, will convene more than 150 representatives from […]
Global Alzheimer’s Platform Foundation recognizes strong, expanding research WASHINGTON, DC (February 19, 2019) – The Global Alzheimer’s Platform Foundation (GAP) announced a $100,000 grant to the Barrow Neurological Foundation to optimize and support the Alzheimer’s clinical trials program at Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center. The grant will go toward participant retention efforts, staff education […]
Grant Funds January 28 Community Event at Ontario Science Centre and Expanded Clinical Trial Education Programs TORONTO – January 22, 2019 —The Global Alzheimer’s Platform Foundation and Toronto Memory Program have initiated a multi-faceted project to educate the Ontario community about Alzheimer’s disease, brain health and the role of Alzheimer’s clinical trials. Toronto Memory Program is a member of the GAP-Net network […]
Event is on November 8, Chicago Alzheimer’s Awareness Day On November 8th – Chicago Alzheimer’s Awareness Day – Great Lakes Clinical Trials and the Global Alzheimer’s Platform Foundation are hosting a major community event for people in the community who are interested in learning more about memory concerns and Alzheimer’s disease. Research volunteers, including care partners, are being honored and celebrated, […]
WASHINGTON, D.C. – “I would like to thank the National Institute on Aging for its thoughtful work on the national strategy. More effective recruitment means faster trials and getting approved therapies to market years sooner. The Global Alzheimer’s Platform Foundation is pleased to join in this effort by building a better research infrastructure through GAP-NET, its […]
Winners to be recognized at UsAgainstAlzheimer’s 2019 National Summit in Washington, D.C. WASHINGTON, D.C. (September 25, 2018) – More than 5.7 million Americans suffer from Alzheimer’s disease and researchers rely upon clinical trial volunteers to be the first step towards a cure. The Global Alzheimer’s Platform Foundation (GAP) has launched the Citizen Scientist Awards®, the first national awards program recognizing and celebrating Alzheimer’s disease clinical […]
Lyft drivers will transport clinical trial participants to and from GAP-Net research sites WASHINGTON, D.C. (Mar. 20, 2018) – The Global Alzheimer’s Platform Foundation has launched a partnership with Lyft to provide transportation for Alzheimer’s clinical trial participants to and from research sites. The partnership began on Feb. 20 with a pilot in California. Transportation will be available for participants and care partners who […]
WASHINGTON, D.C. – “The Global Alzheimer’s Platform Foundation (GAP) enthusiastically welcomes Bill Gates and his team to the fight against Alzheimer’s disease. This epidemic, which affects millions of people worldwide, is growing exponentially and requires new thinking and investment to begin to stem that tide. We at Global Alzheimer’s Platform Foundation are focused on disrupting the Alzheimer’s clinical trial […]
More than Half of All National Clinical Trials in Alzheimer’s Take Place at GAP Networked Sites Kansas City Pilot Program Increased Volunteer Trial Participation by 292% WASHINGTON, D.C. (November 1, 2017) – Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers at least $153 billion dollars per year in Medicare and Medicaid expenses alone. […]
Increase is Part of National Institutes of Health (NIH) $2 Billion Funding Boost Bipartisan Support is Good Newsfor 5.5 Million Americans Living with Alzheimer’s and their Caregivers WASHINGTON, D.C. (May 4, 2017) – The Global Alzheimer’s Platform Foundation, a nonprofit organization dedicated to expediting Alzheimer’s clinical trials, applauds today’s $400 million Congressional increase in Alzheimer’s research funding. Under the bipartisan vote, the National […]
Pascale Witz brings two decades of healthcare leadership experience to GAP Board WASHINGTON, D.C. (Sep. 15, 2016) – Global Alzheimer’s Platform Foundation, Inc. (GAP), a nonprofit organization dedicated to reducing the duration, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Pascale Witz to its Board of Directors. In this role, Pascale will provide counsel based […]
First?of?its?Kind Network of Clinical Trial Sites Quickens Timeline and Quality of Alzheimer’s Clinical Trials WASHINGTON, D.C. (July 28, 2016) – The Global Alzheimer’s Platform Foundation (GAP) announced the launch of GAP?Net, a first?of?its?kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer’s disease. GAP?Net currently has 11 leading academic and private commercial […]